Compare EAT & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EAT | IRTC |
|---|---|---|
| Founded | 1975 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.8B |
| IPO Year | N/A | 2016 |
| Metric | EAT | IRTC |
|---|---|---|
| Price | $136.35 | $172.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | $163.06 | ★ $203.93 |
| AVG Volume (30 Days) | ★ 1.8M | 466.8K |
| Earning Date | 01-28-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.76 | N/A |
| EPS | ★ 9.64 | N/A |
| Revenue | ★ $5,594,400,000.00 | $702,573,000.00 |
| Revenue This Year | $7.80 | $27.20 |
| Revenue Next Year | $5.17 | $16.89 |
| P/E Ratio | $14.14 | ★ N/A |
| Revenue Growth | 23.18 | ★ 25.45 |
| 52 Week Low | $100.30 | $82.12 |
| 52 Week High | $192.22 | $212.00 |
| Indicator | EAT | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 41.95 |
| Support Level | $138.32 | $171.24 |
| Resistance Level | $143.99 | $187.98 |
| Average True Range (ATR) | 6.15 | 7.05 |
| MACD | -0.43 | -0.94 |
| Stochastic Oscillator | 35.37 | 21.72 |
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.